SOURCE: Reliv International, Inc.

Reliv International: The Nutritional Epigenetics Company

February 08, 2017 17:35 ET

Reliv's CardioSentials Heart Health Supplement Awarded Patent

Clinically proven formula earns Dr. Carl Hastings his ninth product patent at Reliv

CHESTERFIELD, MO--(Marketwired - February 08, 2017) - Reliv International, Inc. (NASDAQ: RELV) announced that CardioSentials® heart health supplement has earned a U.S. patent. Reliv first shared the achievement with the company's distributors via a podcast featuring Dr. Carl Hastings, Chief Scientific Officer and the product's creator. Listen to the podcast.

CardioSentials' patented formula contains ingredients shown to support cardiovascular health, including 1.5 grams of phytosterols, in line with the American Heart Association's recommendation of 1.0 to 2.0 grams daily to reduce heart disease risk. Additional ingredients include policosanol, shown to support healthy cholesterol levels and coronary blood flow; CoQ10, a heart-protective antioxidant produced naturally by the body; and OptiBerry®, a patented blend of berry extracts shown to relax arterial walls and increase circulation.

A study published in the Journal of Complementary and Integrative Medicine showed CardioSentials to be effective in lowering risk factors for cardiovascular disease. The double-blind, placebo-controlled clinical trial tested individuals taking statin medications and participants not on statins. For both groups, participants taking CardioSentials significantly reduced total cholesterol, LDL (bad) cholesterol and triglycerides, as well as increased HDL (good) cholesterol and lowered blood glucose levels. View complete study.

"CardioSentials is a powerful addition to any heart health regimen," said Hastings. "The formula brings together a uniquely effective blend of ingredients to deliver real, measurable results. And now we have both a patent and a clinical trial to prove it."

CardioSentials becomes the sixth currently patented Reliv nutritional formula, joining Arthaffect® for joint health, GlucAffect® for blood sugar management, ProVantage® for athletic performance, ReversAge® for anti-aging nutrition and 24K® for energy and focus. Four other Reliv products have also earned patents, but these patents have since expired: Cellebrate® for weight loss, FibRestore® for digestive health, Innergize!® for performance nutrition and Reliv Classic® for essential daily nutrition. In addition, Reliv, through its wholly-owned subsidiary SL Technology, Inc., holds several patents related to lunasin, the active component in LunaRich X™.

"CardioSentials marks the ninth product patent Dr. Carl has earned during his distinguished career at Reliv," said Ryan Montgomery, President. "Those of us in the nutrition industry know what a truly remarkable accomplishment that is. His cutting-edge work is the reason Reliv is known as the home of patented nutrition."

About Reliv International, Inc.

Reliv International, based in Chesterfield, MO, produces nutritional supplements that promote optimal nutrition. Reliv supplements address essential nutrition, fitness and weight loss and targeted solutions. Reliv is the exclusive provider of LunaRich® products, which optimize levels of lunasin, a soy peptide that works at the epigenetic level to promote optimal health. The company sells its products through an international network marketing system of independent distributors in 15 countries. Learn more about Reliv at reliv.com, or on Facebook, Twitter or Instagram.

Statements made in this news release that are not historical facts are "forward-looking" statements (as defined in the Private Securities Litigation Reform Act of 1995) that involve risks and uncertainties and are subject to change at any time. These forward-looking statements may include, but are not limited to, statements containing words such as "may," "should," "could," "would," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" or similar expressions. Factors that could cause actual results to differ are identified in the public filings made by Reliv with the Securities and Exchange Commission. More information on factors that could affect Reliv's business and financial results are included in its public filings made with the Securities and Exchange Commission, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, copies of which are available on the Company's web site, reliv.com.

Contact Information

  • For more information, contact:
    Kurt Wulff
    Vice President of Marketing
    (636) 733-1433